Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables - Net: 2010-2025

Historic Receivables - Net for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $120.4 million.

  • Ironwood Pharmaceuticals' Receivables - Net rose 58.00% to $120.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.4 million, marking a year-over-year increase of 58.00%. This contributed to the annual value of $81.9 million for FY2024, which is 36.57% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Receivables - Net is $120.4 million, which was up 39.68% from $86.2 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Receivables - Net peaked at $138.0 million during Q4 2021, and registered a low of $39.8 million during Q1 2025.
  • Moreover, its 3-year median value for Receivables - Net was $86.2 million (2025), whereas its average is $93.0 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 525.32% in 2021, then slumped by 51.17% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Receivables - Net stood at $138.0 million in 2021, then dropped by 5.80% to $130.0 million in 2022, then fell by 0.68% to $129.1 million in 2023, then slumped by 36.57% to $81.9 million in 2024, then skyrocketed by 58.00% to $120.4 million in 2025.
  • Its last three reported values are $120.4 million in Q3 2025, $86.2 million for Q2 2025, and $39.8 million during Q1 2025.